Azithromycin

Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: There has been renewal of interest in the use of prophylactic antibiotics to reduce the frequency of exacerbations and improve quality of life in chronic obstructive pulmonary disease (COPD). OBJECTIVES: To determine whether or not regular treatment of COPD patients with prophylactic antibiotics reduces exacerbations or affects quality of life. SEARCH METHODS: We searched the Cochrane Airways Group Trials Register and bibliographies of relevant studies. The latest literature search was August 2013.

Author(s): 
Herath, Samantha C.
Poole, Phillippa
Publication Title: 
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

BACKGROUND: Because antimalarial drug resistance is spreading, there is an urgent need for new combination treatments for malaria, which kills >1 million people every year. Azithromycin is a macrolide antibiotic that is particularly attractive as an antimalarial because of its safety in children and the extensive experience with its use during pregnancy. METHODS: We undertook a randomized, controlled, 28-day inpatient trial involving patients with acute, uncomplicated Plasmodium falciparum malaria.

Author(s): 
Noedl, Harald
Krudsood, Srivicha
Chalermratana, Kobsiri
Silachamroon, Udomsak
Leowattana, Wattana
Tangpukdee, Noppadon
Looareesuwan, Sornchai
Miller, Robert Scott
Fukuda, Mark
Jongsakul, Krisada
Sriwichai, Sabaithip
Rowan, Jacqueline
Bhattacharyya, Helen
Ohrt, Colin
Knirsch, Charles
Publication Title: 
Antimicrobial Agents and Chemotherapy

Azithromycin when used in combination with faster-acting antimalarials has proven efficacious in treating Plasmodium falciparum malaria in phase 2 clinical trials. The aim of this study was to establish optimal combination ratios for azithromycin in combination with either dihydroartemisinin or quinine, to determine the clinical correlates of in vitro drug sensitivity for these compounds, and to assess the cross-sensitivity patterns. Seventy-three fresh P.

Author(s): 
Noedl, Harald
Krudsood, Srivicha
Leowattana, Wattana
Tangpukdee, Noppadon
Thanachartwet, Wipa
Looareesuwan, Sornchai
Miller, Robert Scott
Fukuda, Mark
Jongsakul, Krisada
Yingyuen, Kritsanai
Sriwichai, Sabaithip
Ohrt, Colin
Knirsch, Charles
Publication Title: 
PloS One

OBJECTIVE: New anti-malarial regimens are urgently needed in sub-Saharan Africa because of the increase in drug resistance. We investigated the safety and efficacy of azithromycin or artesunate combined with sulfadoxine-pyrimethamine used for treatment of malaria in pregnant women in Blantyre, Malawi. METHODS/FINDINGS: This was a randomized open-label clinical trial, conducted at two rural health centers in Blantyre district, Malawi.

Author(s): 
Kalilani, Linda
Mofolo, Innocent
Chaponda, Marjorie
Rogerson, Stephen J.
Alker, Alisa P.
Kwiek, Jesse J.
Meshnick, Steven R.
Publication Title: 
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

BACKGROUND: Acute febrile illness is the most common cause of outpatient attendance and mortality for children in Africa. Malaria and bacterial disease are difficult to differentiate with limited diagnostic facilities. Combinations of antibiotics and antimalarials are potentially attractive for treatment of the syndrome. Azithromycin plus artesunate (AT+AS) is an effective antimalarial combination for adults in Asia.

Author(s): 
Sykes, Alma
Hendriksen, Ilse
Mtove, George
Mandea, Victor
Mrema, Hedwiga
Rutta, Benadina
Mapunda, Ephraihim
Manjurano, Alphaxard
Amos, Ben
Reyburn, Hugh
Whitty, Christopher J. M.
Publication Title: 
Tropical medicine & international health: TM & IH

OBJECTIVE: Recent clinical studies have shown high rates of malaria treatment failure in endemic areas of Papua New Guinea (PNG), necessitating a change of treatment from chloroquine (CQ) or amodiaquine (AQ) plus sulphadoxine-pyrimethamine to the artemisinin combination therapy (ACT) artemether plus lumefantrine (LM). To facilitate the monitoring of antimalarial drug resistance in this setting, we assessed the in vitro sensitivity of Plasmodium falciparum isolates from Madang Province.

Author(s): 
Wong, Rina P. M.
Lautu, Dulcie
Tavul, Livingstone
Hackett, Sara L.
Siba, Peter
Karunajeewa, Harin A.
Ilett, Kenneth F.
Mueller, Ivo
Davis, Timothy M. E.
Publication Title: 
The Journal of Infectious Diseases

BACKGROUND: In recent studies, the combination of azithromycin and artesunate has proven to be a promising alternative for the treatment of uncomplicated falciparum malaria. METHODS: We conducted a randomized, controlled clinical trial assessing the efficacy of azithromycin-artesunate combination therapy. The study was conducted involving 228 patients aged 8-65 years.

Author(s): 
Thriemer, Kamala
Starzengruber, Peter
Khan, Wasif Ali
Haque, Rashidul
Marma, Aung Swe Prue
Ley, Benedikt
Vossen, Matthias G.
Swoboda, Paul
Akter, Jasmin
Noedl, Harald
Publication Title: 
Antimicrobial Agents and Chemotherapy

Evidence of emerging Plasmodium falciparum resistance to artemisinin-based combination therapies, documented in western Cambodia, underscores the continuing need to identify new antimalarial combinations. Given recent reports of the resurgence of chloroquine-sensitive P. falciparum parasites in Malawi, after the enforced and prolonged withdrawal of this drug, and indications of a possible synergistic interaction with the macrolide azithromycin, we sought to further characterize chloroquine-azithromycin combinations for their in vitro and in vivo antimalarial properties.

Author(s): 
Pereira, Marcus R.
Henrich, Philipp P.
Sidhu, Amar Bir Singh
Johnson, David
Hardink, Joel
Van Deusen, Jeffrey
Lin, Jian
Gore, Katrina
O'Brien, Connor
Wele, Mamadou
Djimde, Abdoulaye
Chandra, Richa
Fidock, David A.
Publication Title: 
Antimicrobial Agents and Chemotherapy

In 18 male healthy subjects, artesunate (200 mg)-azithromycin (1,500 mg) daily for 3 days was found to be well tolerated, with only mild gastrointestinal disturbances reported. The pharmacokinetic properties of artesunate-azithromycin given in combination are comparable to those of the drugs given alone. Artesunate and its major active metabolite, dihydroartemisinin, are responsible for most of the ex vivo antimalarial activity, with a delayed contribution by azithromycin.

Author(s): 
Chinh, Nguyen Trong
Quang, Nguyen Ngoc
Anh, Chu Xuan
Thanh, Nguyen Xuan
Dai, Bui
Birrell, Geoffrey W.
Chavchich, Marina
Edstein, Michael D.
Publication Title: 
Journal of Pharmaceutical and Biomedical Analysis

Near infrared spectroscopy (NIRS) methods were developed for the determination of analytical content of an antimalarial-antibiotic (artesunate and azithromycin) co-formulation in hard gelatin capsule (HGC). The NIRS consists of pre-processing treatment of spectra (raw spectra and first-derivation of two spectral zones), a unique principal component analysis model to ensure the specificity and then two partial least-squares regression models for the determination content of each active pharmaceutical ingredient.

Author(s): 
Boyer, Chantal
Gaudin, Karen
Kauss, Tina
Gaubert, Alexandra
Boudis, Abdelhakim
Verschelden, Justine
Franc, Mickaël
Roussille, Julie
Boucher, Jacques
Olliaro, Piero
White, Nicholas J.
Millet, Pascal
Dubost, Jean-Pierre

Pages

Subscribe to RSS - Azithromycin